PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Sanofi/Sclérose en plaques-Le tolebrutinib allonge de 31% le délai avant progression du handicap Sanofi a annoncé vendredi que le tolebrutinib, son candidat-médicament le plus avancé contre la ...
Some results have been hidden because they may be inaccessible to you